Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/13/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Stephen D. Gillies

Wrong Dr. Stephen D. Gillies?

President and Chief Executive Off...

Provenance Biopharmaceuticals Corp
70 Bedford Rd Suite 545
Carlisle, Massachusetts 01741
United States

Company Description: Provenance Biopharmaceuticals Corp. is a biotechnology company focused on developing novel immunotherapeutics to treat cancer and other serious, life-threatening...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Ph.D
  • Ph.D.
    College of Medicine and Dentistry
  • B.S. degree
    University of Massachusetts
  • M.S. degree
    College of Medicine and Dentistry
23 Total References
Web References
Galenea
www.galenea.com, 13 Mar 2014 [cached]
Stephen Gillies, Ph.D. Dr. Gillies is the founder and CEO of Provenance Biopharmaceuticals Corp., a company focused on the clinical development of a novel recombinant antibody-based immune therapeutic approach to cancer and other serious diseases. He was the past President of EMD Lexigen Pharmaceuticals, a division of Merck KGaA, where he was responsible for advancement of all business and scientific endeavors at the research center since its founding in 1992. Previously, Dr. Gillies was vice president of research at Damon Biotech and Abbott Biotech, Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein. Dr. Gillies received a Master of Science degree and a Ph.D. from Rutgers University in New Jersey and a Bachelor of Science degree from the University of Massachusetts.
Provenance's Management Team ...
www.provenancebio.com, 26 Dec 2013 [cached]
Provenance's Management Team consists of the two company founders, Dr. Stephen Gillies and Mr. Jason Walsh, together with a virtual team of experienced biological research and development experts.
...
Stephen D. Gillies, Ph.D, President and CEO
Dr. Gillies is an expert in the creation and development of recombinant antibodies and immunotherapy. He is inventor of core platform technologies, immunocytokines and Fc-X, for which there are several clinical projects in development with various pharmaceutical companies, research institutes, and government agencies.
Prior to founding Provenance Biopharmaceuticals Corp., Dr Gillies led all scientific and business endeavors of Lexigen Pharmaceuticals Corp. since its founding in 1992 as Fuji Immunopharmaceuticals Corp. In this capacity, he was responsible for numerous funding activities and corporate partnerships,including the acquisition of the Company by Merck KGaA. After Lexigen's acquisition in 1999, Dr. Gillies had the additional responsibility of overseeing Global Oncology Pre-clinical research for Merck KGaA. Previously, he was vice president of research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein. As a postdoctoral fellow at the Massachusetts Institute of Technology, he identified the first cellular enhancer sequences that were found to be critical for the regulation of antibody expression. This discovery proved a key part of the commercial success of Erbitux, a cancer drug marketed by Imclone Systems Inc., Bristol Myers Squibb, and Merck KGaA.
As part of his recombinant antibody project work, Dr. Gillies invented and implemented the immunocytokine technology, and leveraged through his academic network, the first proof of principle of this approach. Through support of the National Cancer Institute and clinicians in both the US and Germany the first clinical trials were conducted. During the course of his scientific career, Dr. Gillies led multiple therapeutic candidates into clinical development for HIV/AIDS and cancer. These include engineered antibodies, NCEs and immunocytokines.
Dr. Gillies received his M.S. degree and Ph.D. from the College of Medicine and Dentistry, Rutgers University and his B.S. degree from the University of Massachusetts, Amherst.
...
Andrew Raubitschek, MD. Chairman of the Department of Cancer Immunotherapeutics and Tumor Immunology at the City of Hope National Medical Center in Duarte, California: Dr. Raubitschek has had a strong interest in immunocytokines for many years and has recently collaborated with Dr. Gillies to create and develop the DI-Leu16-IL2 immunocytokine.
...
Walker Professor in the Departments of Pediatrics, Human Oncology & Genetics, Head of Pediatric Hematology-Oncology, and Associate Director (for translational research) of the Paul P. Carbone Comprehensive Cancer Center, at the University of Wisconsin - Madison: Dr. Sondel is a long-term collaborator of Dr. Gillies working both on pre-clinical proof-of-principle studies, as well as a main driver of the Phase I and II studies of the anti-GD2 targeting immunocytokine, hu14.18- IL2.
...
Prior to work with immunocytokines, Dr. Sondel has been involved in the early clinical studies of IL-2 and worked with Dr. Gillies in the early U.S. studies of the parent antibody, ch14.18, in neuroblastoma and melanoma patients.
...
Drs. Sondel and Gillies are coauthors on more than 10 peer-reviewed journal articles.
...
Professor in the Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla, California: Dr. Gillies and Dr. Reisfeld have been collaborators for more than twenty years.
...
In fact, the first immunocytokines created by Dr. Gillies utilized antibodies (14.18 and KS-1/4) first isolated in Dr. Reisfeld's laboratory in the 1980's.
Potentia Pharmaceuticals
www.potentiapharma.com, 1 Mar 2014 [cached]
Stephen Gillies,
...
Dr. Gillies is an accomplished scientist and business executive. Prior to founding Provenance Biopharmaceuticals Corp., Dr Gillies was founding President of Lexigen Pharmaceuticals Corp. and led the company's acquisition by Merck KGaA. While at Merck KGaA, Dr. Gillies led the global pharmaceutical company's pre-clinical oncology research. Previously, he was vice president of research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein. During the course of his scientific career, Dr. Gillies has led multiple therapeutic candidates into clinical development for HIV/AIDS and cancer. These include engineered antibodies, NCEs and immunocytokines. Dr. Gillies has his M.S. degree and Ph.D. from the College of Medicine and Dentistry, Rutgers University and his B.S. degree from the University of Massachusetts, Amherst.
Provenance Biopharmaceuticals ...
www.provenancebio.com, 26 Dec 2013 [cached]
Provenance Biopharmaceuticals was founded in 2008 to continue the development of "immunocytokines" (antibody-cytokine fusion proteins) pioneered by Provenance founder, Dr. Stephen Gillies in the early 1990s. he company's lead molecule, DI-Leu16-IL2, is a second-generation immunocytokine being tested in human clinical trials for the treatment of CD20-positive hematological cancers.
Provenance Biopharmaceuticals ...
www.provenancebio.com, 26 Dec 2013 [cached]
Provenance Biopharmaceuticals was founded in 2008 to continue the development of "immunocytokines" an antibody-cytokine fusion technology pioneered by Provenance founder, Dr. Stephen Gillies in the early 1990s.
Other People with the name "Gillies":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304